A Post-Market Clinical Follow-Up on Safety and Performance of the Ophthalmic Viscoelastic Devices Eyefill SC and Eyefill MB

Inclusion Criteria: * Adult subjects scheduled for cataract surgery with im-plantation of a posterior chamber intraocular lens; * Signed informed consent; * Availability, willingness, ability, and sufficient cognitive awareness to comply with examination procedures Exclusion Criteria: * Known hypersensitivity to sodium hyaluronate; * Corneal endothelial cell density \<1500 cells/mm2; * Corneal abnormalities; * Cataract density of grade 4+; * Previous intraocular or corneal surgery; * Chronic or recurrent inflammatory eye diseases (e.g., iritis, scleritis, iridocyclitis, or rubeosis iridis); * Clinically significant, uncontrolled glaucoma with expected negative impact on visual acuity outcomes; * Ongoing systemic or ocular steroid therapy; * Diagnosed degenerative visual disorders (e.g. macular degeneration or other retinal or optic disorders) that are predicted to cause future acuity loss to 20/30 or worse in one or both eyes; * Active ocular or systemic infection (bacterial, viral, or fungal), including fever * Subjects who may be expected to require a combined or other secondary surgical procedure * Females of childbearing potential (those who are not surgically sterilized or not postmenopausal for at least 12 months) if they meet one of the following conditions: Pregnant, lactating or unwilling to use effective birth control over the course of the study; * Concurrent or previous (within 30 days) participation in another drug or device investigation.